Not yet recruiting NCT06543030
Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Hepatocellular Carcinoma. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma
Detailed description
To compare transfemoral approach (TFA) and transradial approach (TRA) in patients undergoing hepatic chemoembolization in terms of safety, feasibility, and procedural variables, including fluoroscopy time and patient preference.
Primary outcome measures
- To compare transfemoral approach (TFA) and transradial approach (TRA) in patients undergoing hepatic chemoembolization [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Patients with Hepatocellular carcinoma of BCLC (Barcelona Clinic Liver Cancer) stage B
- Also for BCLC stage A patients, in whom ablative therapy has technical limitations.
- Downsizing tumor for resection or transplantation.
Exclusion criteria
- Factors related to liver cirrhosis:
- Decompensated cirrhosis (Child-Pugh B and C, score >8), including jaundice, clinical hepatic encephalopathy, and refractory ascites and/ or hepatorenal syndrome
- Impaired portal-vein blood flow (portal-vein thrombus, hepatofugal blood flow)
- Factors related to HCC:
- Extensive tumor involving the entirety of both lobes of the liver
- Malignant portal vein thrombosis
- Extra-hepatic metastases
- Impaired renal function:
- Creatinine ≥2 mg/dl or creatinine clearance <30 ml/min
- Factors related to procedure (Radial artery access):
- Existing AV (arteriovenous) fistula or graft
- Pervious major surgery to forearm or wrist
- Vasculitis
- Pervious access failure
- Skin infection or compromised integrity
- Artery size <2mm
- Intolerance of hyperextended wrist positioning
- Severe vasospasm
- Vessel tortuosity
- Radial loops
- Absent or occluded radial artery
- Atherosclerotic or calcific PAD (peripheral artery disease)
- Coagulopathy INR>1.5 platelets count <50.000/mmc
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
Egypt · 1 center
- Assiut University hospitals — Asyut
Identifiers
NCT: NCT06543030 · TACE